BET inhibitor and CDK4/6 inhibitor synergistically inhibit breast cancer by suppressing BRD4 stability and DNA damage repair
Translational Oncology · 2025-01 · 51 · 102212
DOI: 10.1016/j.tranon.2024.102212 ↗Kurz gefasst
Fachartikel in der Zeitschrift Translational Oncology, 2025-01. Verfasst von Shuaishuai Chi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Basic Medical Sciences, Zhejiang University School of Medicine, Hangzhou, Zhejiang 0310058, China; State Key Laboratory of Chemical Bio…. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
CDK4/6 inhibitors have shown clinical benefits in hormone receptor positive breast cancer. However, monotonous indications and unclear resistance mechanisms greatly limit the clinical application of these inhibitors. We attempt to improve the therapeutic effect of CDK4/6 inhibitors against breast cancer by combination with BET inhibitors. Although this combination therapy has begun to be studied in recent clinical trials, the mechanism of action is not clear. We provide the evidence that CDK4/6 inhibitor LY2835219 plus BRD4 inhibitor OTX-015 synergistically inhibits both ER positive and triple-negative breast cancer cells growth in vitro and in vivo. Mechanistically, LY2835219 accelerates the degradation of BRD4 through the proteasome pathway via inhibition of CDK4 activity. This instability of BRD4 protein in turn enhances the anti-tumor effect of CDK4/6 inhibitor by suppressing transcription of DNA damage repair gene RAD51, and synergistically promotes γ-H2AX accumulation and DNA double-strand breaks. Overall, we demonstrated the potential combined therapeutic value of CDK4/6 and BRD4 inhibitors and elucidated the mechanisms, which may provide a new rational approach for breast cancer patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Basic Medical Sciences, Zhejiang University School of Medicine, Hangzhou, Zhejiang 0310058, China; State Key Laboratory of Chemical Biology, Chinese Academy of Sciences, Shanghai Institute of Materia Medic…
- State Key Laboratory of Chemical Biology, Chinese Academy of Sciences, Shanghai Institute of Materia Medica, Shanghai 201203, China. Electronic address: weifan3@simm.ac.cn.
- State Key Laboratory of Chemical Biology, Chinese Academy of Sciences, Shanghai Institute of Materia Medica, Shanghai 201203, China; University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, China.
- State Key Laboratory of Chemical Biology, Chinese Academy of Sciences, Shanghai Institute of Materia Medica, Shanghai 201203, China; University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, China;…
- State Key Laboratory of Chemical Biology, Chinese Academy of Sciences, Shanghai Institute of Materia Medica, Shanghai 201203, China.
- Department of Basic Medical Sciences, Zhejiang University School of Medicine, Hangzhou, Zhejiang 0310058, China; University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, China; Shandong Laboratory…
Zitieren
APA
Chi, S., Wei, F., Li, Y., Yu, L., Ma, C., Fang, Y., Yang, B., Chen, Y., & Ding, J. (2025). BET inhibitor and CDK4/6 inhibitor synergistically inhibit breast cancer by suppressing BRD4 stability and DNA damage repair. Translational Oncology, 51, 102212. https://doi.org/10.1016/j.tranon.2024.102212
Vancouver
Chi S, Wei F, Li Y, Yu L, Ma C, Fang Y, et al. BET inhibitor and CDK4/6 inhibitor synergistically inhibit breast cancer by suppressing BRD4 stability and DNA damage repair. Translational Oncology. 2025;51:102212. doi:10.1016/j.tranon.2024.102212
BibTeX
@article{Chi2025,
author = {Chi, Shuaishuai and Wei, Fan and Li, Yangsha and Yu, Lei and Ma, Chuyao and Fang, Yanfen and Yang, Biyu and Chen, Yi and Ding, Jian},
title = {BET inhibitor and CDK4/6 inhibitor synergistically inhibit breast cancer by suppressing BRD4 stability and DNA damage repair},
journal = {Translational Oncology},
year = {2025},
volume = {51},
pages = {102212},
doi = {10.1016/j.tranon.2024.102212}
}
EUVIMED